Institutional members access full text with Ovid®

Retinal Abnormalities and Blue Skin from Antiseizure Drug

Aschenbrenner, Diane S. MS, RN

AJN, American Journal of Nursing: August 2013 - Volume 113 - Issue 8 - p 23
doi: 10.1097/01.NAJ.0000432957.11010.12
Drug Watch

* The Food and Drug Administration has issued a warning that some patients taking ezogabine (Potiga) to control seizures have developed pigment changes in the retina or blueness in their skin.

* These adverse effects are becoming evident after prolonged use of ezogabine.

Diane S. Aschenbrenner recently retired from her position as course coordinator for undergraduate pharmacology at Johns Hopkins University School of Nursing in Baltimore, MD. She also coordinates Drug Watch: daschen1@jhu.edu.

© 2013 Lippincott Williams & Wilkins. All rights reserved.